TGBA01AD
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT 1A and 5-HT 1D receptor agonist, and 5-HT 2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.
TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT 1A and 5-HT 1D receptor agonist, and 5-HT 2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder. It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372053586 under CC BY-SA 4.0; modifications have been made.